Heart failure patients who are treated with stem cell therapy may have fewer cardiac events, researchers, including one of Indian -origin, have found. End-stage heart failure patients treated with stem cells harvested from their own bone marrow experienced 37 per cent fewer cardiac events - including hospital admissions related to heart failure -- than a placebo-controlled group. This is the first trial of cell therapy showing that it can have a meaningful impact on the lives of patients with heart failure. Other cell therapy trials tested single stem cell populations and did not report impacts on the end results of death or other heart related clinical outcomes, researchers said. The findings were published in the journal Lancet.